Material Methods: Nephroprotective activity of the test drug was evaluated in wistar rats. Animals were allocated into 6 groups of 6 animals in each. Group I served as plain control and group II served as negative control in which toxicity was induced by using Gentamicin (80 mg/kg IM once daily for 12 days). Third group served as concurrent test group A was administered with ethanolic extract of Beekh Kasni (3.4 mg/kg orally once daily for 12 days along with Gentamicin 80 mg/kg IM). Fourth group served as concurrent test group B was administered with aqueous extract of Beekh Kasni (3.4 mg/ kg orally once daily for 12 days). Fifth and Sixth group served as pre treated groups were initially administered ethanolic and aqueous extract of Beekh Kasni 3.4mg/kg respectively orally once daily for 15 days and subsequently Gentamicin 80mg/kg IM once daily administered for the next 12 days. On the 13^th day the animals were anaesthetized using phenobarbitone at the dose of dose 50mg/kg, blood was collected by cardiac puncture for the estimation of serum cretinine and serum urea (Bayers) using auto analyzer.

Results: Present study revealed that the test drug possesses significant nephroprotective activity. Two important markers of kidney (Serum Urea and Serum Creatinine) were decreased. Nephroprotective activity was further confirmed by findings of histopathological examination of the kidney tissues where the structural integrity was brought to near normal level in both concurrent and pretreated group of animals.

Conclusion: The test drug Beekh Kasni possesses a significantly high level of nephroprotective effect and the findings validated the Unani description of the test drug.